CoChat

The storm has cleared: lessons from the CD28 superagonist TGN1412 trial

Hünig, Thomas · 2012 · Nature Reviews Immunology

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The life-threatening cytokine-release syndrome suffered by six volunteers in a Phase I clinical trial following administration of the CD28 superagonist antibody TGN1412 (developed by TeGenero) in March 2006 was completely unpredicted by the preclinical studies. Here, Thomas Hünig, main founder of TeGenero, describes the recent investigations into what went wrong and discusses the lessons learnt for future clinical trials.

Overview

Integrity signals

Registry

Crossref · 10.1038/nri3192

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 14 references

Cited by

See all 194

Metadata

Authors
Hünig, T.
Affiliations
University of Würzburg (DE)
Corresponding author
Hünig, Thomas
Venue
Nature Reviews Immunology
Published
2012-04-10
Volume
12
Issue
5
Pages
317-318
ISSN
  • 1474-1733 (ISSN-L)
  • 1474-1741
OpenAlex
W2080341180
Cited by
194
References
14
Citations by year
2026: 8 · 2025: 2 · 2024: 14 · 2023: 11 · 2022: 3 · 2021: 16 · 2020: 10 · 2019: 17 · 2018: 16 · 2017: 19 · 2016: 20 · 2015: 21 · 2014: 15 · 2013: 16 · 2012: 6
FWCI
14.00
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature reviews. Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TGN1412, cytokine release syndrome
MeSH terms
Adult, Animals, Clinical Trials as Topic, Humans, Leukocytes, Mononuclear, Male, Clinical Trials, Phase I as Topic, Young Adult, Immunomodulation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. https://app.cochat.ai/papers/10.1038/nri3192
The paper
Hünig, T. (2012). The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nature Reviews Immunology. https://doi.org/10.1038/nri3192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.